JPRN-jRCT2052230115招募中1 期
An exploratory study of angiogenic therapy by autologous peripheral blood mononuclear cell-bearing ICS-001 transplantation in patients with chronic limb-threatening ischemia (CLTI) with refractory ulcers
Kenichi Yamahara0 个研究点目标入组 6 人开始时间: 2023年10月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Patients who meet all of the following criteria are eligible:
- •(1) Patients with arteriosclerosis obliterans (ASO) or Buerger's disease
- •(2) Patients with confirmed occlusion or stenosis by angiography, MRA, or CTA of the lower extremities within 6 months prior to obtaining consent
- •(3) Patients with Ischemia grade 2 or higher in WIfI classification
- •(4) Patients with refractory ulcers of Wound grade 1 and Foot Infection grade 1 or lower in the WIfI classification, that are not suitable for revascularization (endovascular treatment or bypass surgery) or that do not heal for more than 4 weeks despite revascularization, Wound grade 1 and Foot Infection grade 1 or lower in the WIfI classification or refractory ulcers
- •(5) Non-smoker or patients who have stopped smoking for at least 1 month, and are able to quit smoking throughout the study period (only for Buerger's disease patients)
- •(6) Patients who are more than 20 years old and less than 85 years old at the time of consent, and whose written consent has been obtained
排除标准
- •Patients who meet any of the following criteria should be excluded:
- •(1) Patients scheduled for major amputation
- •(2) Patients with Wound grade 0 or 2 or higher in WIfI classification
- •(3) Patients with Ischema grade 1 or lower in WIfI classification
- •(4) Patients with Foot infection grade 2 or higher in WIfI classification
- •(5) Patients who underwent revascularization, sympathectomy/sympathetic ganglion block, cell therapy/gene therapy, or minor amputation for the purpose of CLTI treatment in the lower extremities to which ICS-001 will be implanted within 4 weeks prior to obtaining consent
- •(6) Patients with poorly controlled ischemic heart disease or heart failure
- •(7) Patients with poorly controlled diabetes mellitus
- •(8) Patients with severe hepatic dysfunction
- •(9) Patients with severe chronic kidney disease (under 30 mL/min/1.73 m2 of eGFR )
- •(10) Patients undergoing hemodialysis or peritoneal dialysis or post renal transplantation
- •(11) Patients with a history of serious hypersensitivity or adverse reactions to Filgrastim (Gran), Plerixafol (Mozobil), and Apheresis
- •(12) Patients with concomitant or pre-existing interstitial pneumonia
- •(13) Patients with leukemia, myeloproliferative disorders, or myelodysplastic syndrome
- •(14) Patients who have undergone percutaneous coronary intervention within 2 months prior to obtaining consent
- •(15) Patients complicated with malignant tumors
- •(16) Patients with untreated proliferative diabetic retinopathy (modified Davis classification: proliferative retinopathy)
- •(17) Patients with infectious diseases associated with a fever of 38 degree or higher
- •(18) Patients with hypoalbuminemia (albumin level less than 3.0 g/dL)
- •(19) Patients with low BMI (under 18)
- •(20) Patients with claudication, pain at rest, skin ulcer, or gangrene due to other factors not caused by the primary disease
- •(21) Patients with psychiatric disorders that are difficult to control
- •(22) Patients with clinically problematic splenomegaly
- •(23) Patients who are participating in other clinical trials or who have not completed a previous clinical trial more than 3 months after the completion of the previous trial
- •(24) Pregnant women, lactating women, female patients who may be pregnant or planning to become pregnant by the end of the study period, or male patients whose partners wish to become pregnant
- •(25) Patients who are unlikely to survive beyond 12 months after the date of consent
- •(26) Other patients who are judged by the investigator or subinvestigator to be inappropriate as subjects for this clinical trial.
研究者
相似试验
招募中
不适用
Total Autologous Angiogenic Therapy with Cultured Bone Marrow Derived Mesenchymal Stromal Cells Grown in Platelet-Rich Plasma Against Peripheral Arterial Disease. - Advanced Medical CarePeripheral arterial diseaseJPRN-jRCTb030210146Fukuda Shoji50
已完成
1 期
Clinical Study of Therapeutic Angiogenesis Using Hypoxic Preconditioned Peripheral Blood Mononuclear CellsPeripheral arterial occlusive diseaseJPRN-UMIN000018594Yamaguchi University Graduate School of Medicine Department of Surgery and Clinical Science7
未知
不适用
Multicenter trial of therapeutic angiogenesis in patients with intractable vasculitisJPRN-UMIN000000939Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine40
已完成
1 期
Vascular regeneration therapy using autologous peripheral blood mononuclear cells for refractory skin ulcer associated with connective tissue diseases and vasculitisPatients with refractory skin ulcers resistant to normal treatment, mainly caused by connective tissue diseases and vasculitisJPRN-UMIN000024255Kumamoto University10
已完成
不适用
Therapeutic Angiogenesis using Autologous Bone-Marrow Mononuclear Cells ImplantatioCLI(Critical limb ischemia) (ASO, Buerger disease, Collagen disease)JPRN-UMIN000023282Kyoto Prefectural University School of Medicine120